HGF induces a protective effect in a mouse model of cholestasis

SALAS SILVA E.S.; SIMONI NIEVES A.; ROSALES CRUZ P.; MÉNDEZ SÁNCHEZ N.; ROMA M.G.; GÓMEZ QUIROZ L.E.; GUTIÉRREZ RUÍZ M.C.

Veracruz, Mexico

Congreso; XI Congreso Nacional de Hepatología de la Asociación Mexicana de Hepatología; 2016

Asociación Mexicana de Hepatología

Background.Cholestatic liver diseases are among the most seriousdiseasesaffecting the liver. Treatments are not optimized; more research is necessaryin order to improve treatment options. It has been observed that hepatocytegrowth factor (HGF) can display protective effects that could supportconventional therapies against cholestasis.Objective.The aim of this work was to address the protective effect of HGF incholestasis induced by alpha-naftylisotiocianate (ANIT).Materialand methods. CD1 mice were treated with ANIT (60 ug/kg, ig), 24 hafter the toxic treatment, 10 ug/kg, iv of HGF was administrated. Animals weresacrificed 24 h after HGF treatment. Liver function test, and routing H&Estaining were performed. Main molecular markers of damage and protection wereaddressed by Western blotting and RTPCR.Results.ALT, AST and ALP were increased by ANIT treatment, and HGF reduced theseparameters. Histology showed tissue damage, particularly necrosis andinflammatory infiltration. HGF improved these findings. Molecular studiesrevealed the increment of Abcc3, Abcc2 and Cyp7a1 by HGF in comparison withANIT alone treatment, this effect was associated by the activation of NRF2. Conclusions.HGF induced a protective effect decreasing necrosis and inflammation, andimproving the main liver function markers, this effect was associated to anincrement in the expression of phase 3 detoxification proteins. HGF could beconsidered as adjuvant in the treatment of cholestasis.